VXSPR
Contract intelligence
Workspace
Home
Dashboard
Contracts
ROI Calculator
Outcomes
Predictive Insights
Report Generator
Data Explorer
Settings
Synthetic demo data only. Not for clinical use.
Toggle Sidebar
VXSPR
Therapeutic contract ROI intelligence
Demo Mode
AM
Client Report Generator
Generate a client-facing ROI report from any contract.
Contract
Copy
Download .txt
Download .csv
Preview
THERAPYROI — CLIENT ROI REPORT ================================ Generated: 7/22/2026 Contract: CT-1000 Client: Meridian Health Plan (Payer, Midwest) Therapy area: Oncology Therapy: OncoTarget-7 Term: 2023-01-01 → 2025-01-01 EXECUTIVE SUMMARY ----------------- The OncoTarget-7 value-based agreement is currently AT RISK, generating a projected -14.2% ROI over the reporting period. Reduced inpatient utilization (791 avoided hospitalizations) and improved therapy adherence (74.3% portfolio average) are the primary drivers of value delivered to Meridian Health Plan. CONTRACT OVERVIEW ----------------- Covered lives: 59,959 Contract cost: $1,400,362 Target adherence: 80% Target readmission ↓: 15% Rebate terms: 5% rebate at risk KEY FINANCIAL METRICS --------------------- Gross savings: $1,200,844 Contract cost: $1,400,362 Net savings: -$199,518 ROI: -14.2% Savings / life: -$3 PMPM: $-0.28 OUTCOME IMPROVEMENTS -------------------- Avoided hospitalizations: 791 Avoided ER visits: 1,639 Average adherence: 74.3% ROI CALCULATION --------------- ROI = (Gross Savings − Contract Cost) / Contract Cost × 100 = ($1,200,844 − $1,400,362) / $1,400,362 × 100 = -14.2% FORECASTED VALUE (NEXT 12 MONTHS) --------------------------------- Projected gross savings: $1,344,945 Projected ROI uplift: +12% based on current trajectory RENEWAL RECOMMENDATION ---------------------- Renew with revised performance thresholds and enhanced patient support. ACCOUNT MANAGER TALKING POINTS ------------------------------ • Lead with -14% ROI and $-199.5K net savings. • Emphasize 791 avoided hospitalizations as direct cost avoidance. • Highlight 74% adherence — above industry benchmark of 65%. • Position renewal around expanding cohorts and deepening patient support. DISCLAIMER ---------- All data shown is synthetic demo data. VXSPR is intended for financial and operational ROI analytics only and is not a medical device, diagnostic tool, treatment recommendation system, or substitute for clinical judgment.